Cardio Diagnostics Holdings (CDIO) Change in Receivables (2022 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Change in Receivables of -$3852.0 for Q1 2026, down 24.46% sequentially from -$3095.0 in Q4 2025, and up 57.48% YoY from -$2446.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Change in Receivables (2022 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Change in Receivables for 5 years, with the latest figure at -$3852.0 in Q1 2026.
- Quarterly Change in Receivables rose 57.48% year-over-year to -$3852.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5278.0 (up 44.07% YoY) and the FY2025 annual result came in at -$10486.0, down 176.81% from the prior year.
- Change in Receivables fell to -$3852.0 in Q1 2026 per CDIO's latest filing, from -$3095.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $14028.0 in Q1 2024 and troughed at -$11468.0 in Q2 2024.
- A 5-year average of $259.46 and a median of -$700.0 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 1040.0% in 2024, down 1192.19% in 2024.
- Over 5 years, Change in Receivables stood at -$901.0 in 2022, then soared by 611.65% to $4610.0 in 2023, then slipped by 2.13% to $4512.0 in 2024, then slumped by 168.59% to -$3095.0 in 2025, then dropped by 24.46% to -$3852.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$3852.0, -$3095.0, and -$1706.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | - |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | -369.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -369.00 |
| Jun 30, 2026 | -369.00 |
| Mar 31, 2026 | -3,852.00 |
| Mar 31, 2026 | -3,852.00 |
| Dec 31, 2025 | -3,095.00 |
| Dec 31, 2025 | -3,095.00 |
| Sep 30, 2025 | -1,706.00 |
| Sep 30, 2025 | -1,706.00 |
| Jun 30, 2025 | 3,375.00 |
| Jun 30, 2025 | 3,375.00 |
| Mar 31, 2025 | -9,060.00 |
| Mar 31, 2025 | -9,060.00 |
| Dec 31, 2024 | 4,512.00 |
| Dec 31, 2024 | 4,512.00 |
| Sep 30, 2024 | 6,580.00 |
| Sep 30, 2024 | 6,580.00 |
| Jun 30, 2024 | -11,468.00 |
| Jun 30, 2024 | -11,468.00 |
| Mar 31, 2024 | 14,028.00 |
| Mar 31, 2024 | 14,028.00 |